Translational Development Acquisition Corp. (TDAC)

TDAC Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	0.22	0	0
Cash & Short-Term Investments	0.22	0	0
Cash Growth	9969.12%	-9.17%	-
Prepaid Expenses	-	-	0.05
Total Current Assets	0.22	0	0.05
Long-Term Deferred Charges	0.17	-	0.38
Total Assets	0.39	0	0.44
Accrued Expenses	0.31	0.16	0.2
Short-Term Debt	0.66	0.35	0.26
Other Current Liabilities	-	-	-0
Total Current Liabilities	0.96	0.51	0.46
Total Liabilities	0.96	0.51	0.46
Common Stock	0	0	0
Additional Paid-In Capital	0.02	0.02	0.02
Retained Earnings	-0.6	-0.53	-0.05
Shareholders' Equity	-0.57	-0.51	-0.02
Total Liabilities & Equity	0.39	0	0.44
Total Debt	0.66	0.35	0.26
Net Cash (Debt)	-0.43	-0.35	-0.26
Net Cash Per Share	-0.11	-0.09	-0.06
Filing Date Shares Outstanding	4.05	4.66	4.05
Total Common Shares Outstanding	4.05	4.66	4.05
Working Capital	-0.74	-0.51	-0.41
Book Value Per Share	-0.14	-0.11	-0.01
Tangible Book Value	-0.57	-0.51	-0.02
Tangible Book Value Per Share	-0.14	-0.11	-0.01

Updated Nov 20, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q